8 January 2025 - NMPA approval based on the global Phase 3 EV-302 trial (also known as KEYNOTE-A39) where the treatment combination significantly improved overall survival and progression-free survival outcomes.

Astellas Pharma today announced that China's National Medical Products Administration has approved Padcev (enfortumab vedotin) in combination with Keytruda (pembrolizumab) for adult patients with locally advanced or metastatic urothelial cancer.

Read Astellas press release